| Item | Value |
|---|---|
| DrugBank ID | DB01030 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 25 |
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | primary non-gestational choriocarcinoma of ovary | TxGNN Knowledge Graph |
| 2 | malignant sex cord stromal tumor of ovary | TxGNN Knowledge Graph |
| 3 | cervical carcinosarcoma | TxGNN Knowledge Graph |
| 4 | malignant non-dysgerminomatous germ cell tumor of ovary | TxGNN Knowledge Graph |
| 5 | ovarian cancer | TxGNN Knowledge Graph |
| 6 | small cell lung carcinoma | TxGNN Knowledge Graph |
| 7 | ovarian clear cell adenocarcinoma | TxGNN Knowledge Graph |
| 8 | ovarian mucinous adenocarcinoma | TxGNN Knowledge Graph |
| 9 | immature ovarian teratoma | TxGNN Knowledge Graph |
| 10 | hereditary site-specific ovarian cancer syndrome | TxGNN Knowledge Graph |
| 11 | cervical carcinoma | TxGNN Knowledge Graph |
| 12 | ovarian adenocarcinoma | TxGNN Knowledge Graph |
| 13 | ovarian small cell carcinoma | TxGNN Knowledge Graph |
| 14 | theca steroid-producing cell malignant tumor of ovary, not further specified | TxGNN Knowledge Graph |
| 15 | hereditary breast ovarian cancer syndrome | TxGNN Knowledge Graph |
| 16 | borderline epithelial tumor of ovary | TxGNN Knowledge Graph |
| 17 | maligant granulosa cell tumor of ovary | TxGNN Knowledge Graph |
| 18 | cervical cancer | TxGNN Knowledge Graph |
| 19 | malignant dysgerminomatous germ cell tumor of ovary | TxGNN Knowledge Graph |
| 20 | familial ovarian cancer | TxGNN Knowledge Graph |
| 21 | ovarian endometrioid adenocarcinoma | TxGNN Knowledge Graph |
| 22 | ovarian carcinosarcoma | TxGNN Knowledge Graph |
| 23 | yolk sac tumor | TxGNN Knowledge Graph |
| 24 | malignant germ cell tumor of ovary | TxGNN Knowledge Graph |
| 25 | malignant Sertoli-Leydig cell tumor of ovary | TxGNN Knowledge Graph |
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.